AQR Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

AQR Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,464	Closed	-$17K	–	2357
2016 Q1	$17K	Sell	11,464 -28,036	-71%	-$55.3K	﹤0.01%	2203
2015 Q4	$126K	Hold	39,500	–	–	﹤0.01%	2201
2015 Q3	$247K	Sell	39,500 -12,600	-24%	-$118K	﹤0.01%	1992
2015 Q2	$517K	Hold	52,100	–	–	﹤0.01%	1764
2015 Q1	$384K	Hold	52,100	–	–	﹤0.01%	1788
2014 Q4	$279K	Hold	52,100	–	–	﹤0.01%	2237
2014 Q3	$262K	Sell	52,100 -1,300	-2%	-$7.99K	﹤0.01%	2236
2014 Q2	$358K	Buy	+53,400	New	+$340K	﹤0.01%	2133

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AQR Capital Management's NWBO Position: Q2 2016 in Review

AQR Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 11,464 shares — an estimated $17K sold.

AQR Capital Management first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $517K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

AQR Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
AQR Capital Management sold 11,464 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $17K.
AQR Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
AQR Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $517K in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on AQR Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.